| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Jan, 2026 | Jan, 2026 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -96,630 | -38,520 | 0 | 0 | 0 |
| Net Income Growth | -150.86% | unch | unch | unch | unch |
Pardes Biosciences Inc (PRDS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pardes Biosciences Inc. is a clinical-stage biopharmaceutical company. It discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company's lead product candidate includes PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences Inc., formerly known as FS Development Corp. II, is based in SAN FRANCISCO, Calif.
Fiscal Year End Date: 12/31